Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention.

Paré G, Eikelboom JW, Sibbing D, Bernlochner I, Kastrati A.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):514-21; discussion 521. doi: 10.1161/CIRCINTERVENTIONS.111.962142. No abstract available.

2.

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.

Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):505-13; discussion 513. doi: 10.1161/CIRCINTERVENTIONS.111.962183. Review. No abstract available.

3.

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.

Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):422-8. doi: 10.1161/CIRCINTERVENTIONS.111.963025. Epub 2011 Oct 4.

4.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

5.

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.

6.

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.

Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA.

J Thromb Haemost. 2013 Jan;11(1):81-91. doi: 10.1111/jth.12059.

7.

Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?

Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, Ohman EM.

Thromb Haemost. 2012 Jul;108(1):12-20. doi: 10.1160/TH12-01-0039. Epub 2012 May 25. Review.

PMID:
22627684
8.

Standard- vs high-dose clopidogrel after percutaneous coronary intervention.

Jeong YH, Park Y, Kim IS.

JAMA. 2011 Jun 22;305(24):2520; author reply 2521-2. doi: 10.1001/jama.2011.842. No abstract available.

PMID:
21693737
9.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

10.

Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel.

Osnabrugge RL, Kappetein AP, Janssens AC.

JAMA. 2011 Feb 2;305(5):467-8; author reply 468. doi: 10.1001/jama.2011.77. No abstract available.

PMID:
21285422
11.

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.

Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.

Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268. Epub 2010 Dec 22.

PMID:
21178986
12.

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY.

Thromb Res. 2011 Jan;127(1):23-8. doi: 10.1016/j.thromres.2010.10.021.

PMID:
21075428
13.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
14.

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators.

J Am Coll Cardiol. 2012 May 29;59(22):1928-37. doi: 10.1016/j.jacc.2011.11.068.

15.

Genetic determinants of on-clopidogrel high platelet reactivity.

Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R.

Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Epub 2011 May 31. Review.

PMID:
21627411
17.

Clopidogrel: to test or not to test? That is the question--still.

Cannon CP.

Clin Chem. 2011 May;57(5):659-61. doi: 10.1373/clinchem.2010.158709. Epub 2011 Mar 14. No abstract available.

18.

Current status of clopidogrel pharmacogenomics.

Giusti B, Gori AM, Marcucci R, Abbate R.

Pharmacogenomics. 2012 Nov;13(15):1671-4. doi: 10.2217/pgs.12.153. No abstract available.

PMID:
23171330
19.

Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.

Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H.

Thromb Res. 2011 Dec;128(6):e130-6. doi: 10.1016/j.thromres.2011.07.028. Epub 2011 Aug 20.

PMID:
21862109
20.

Clopidogrel, genetics, and drug responsiveness.

Freedman JE, Hylek EM.

N Engl J Med. 2009 Jan 22;360(4):411-3. doi: 10.1056/NEJMe0810513. No abstract available.

PMID:
19164193

Supplemental Content

Support Center